Eventide Asset Management LLC Buys Shares of 786,990 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

by · The Markets Daily

Eventide Asset Management LLC bought a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 786,990 shares of the company’s stock, valued at approximately $15,150,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at approximately $27,000. Values First Advisors Inc. bought a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at approximately $30,000. nVerses Capital LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at approximately $33,000. Quantbot Technologies LP bought a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at approximately $49,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares in the last quarter.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock opened at $16.51 on Friday. Syndax Pharmaceuticals, Inc. has a twelve month low of $15.00 and a twelve month high of $25.34. The stock’s 50 day moving average is $18.47 and its 200 day moving average is $19.84.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period in the prior year, the business posted ($0.73) earnings per share. On average, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. HC Wainwright upped their target price on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. Citigroup upped their price target on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. StockNews.com lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. Bank of America upped their target price on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Finally, Stifel Nicolaus lifted their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $37.64.

Read Our Latest Research Report on SNDX

Syndax Pharmaceuticals Company Profile

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Further Reading

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report).